Samarth Kulkarni - 10 Mar 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 10 Mar 2025
Net transactions value: -$616,348
Form type: 4
Filing time: 12 Mar 2025, 19:05:06 UTC
Previous filing: 21 Feb 2025
Next filing: 18 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+19,250	+11%		190,863	10 Mar 2025	Direct	F1
transaction	CRSP	Common Shares	Sale	$423,055	-9,973	-5.2%	$42.42	180,890	11 Mar 2025	Direct	F2
transaction	CRSP	Common Shares	Options Exercise		+9,000	+5%		189,890	11 Mar 2025	Direct	F1
transaction	CRSP	Common Shares	Sale	$193,294	-4,462	-2.3%	$43.32	185,428	12 Mar 2025	Direct	F2
holding	CRSP	Common Shares						85,622	10 Mar 2025	The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-19,250	-33%		38,500	10 Mar 2025	Common Shares	19,250		Direct	F1, F3
transaction	CRSP	Restricted Stock Units	Options Exercise		-9,000	-100%		0	11 Mar 2025	Common Shares	9,000		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3	This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
F4	This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.